The user facility reported to terumo cardiovascular that prior to cardiopulmonary bypass, during out of box, it was observed that there is a more noticeable coating on the inside of the reservoir compared to the (b)(6) reservoir.It has not impacted the function, just concerned.No known impact or consequence to patient.
|
This follow-up report is submitted to the fda in accord with applicable regulations - and as indicated by terumo cardiovascular system in the initial report submitted to the fda on october 20, 2016.Upon further investigation of the reported event, the following information is new and/or changed: (date received by manufacturer), (indication that this is a follow-up report), (follow-up due to additional information), (b)(4).The sample was not returned for evaluation; however, a photo was provided showing the visual anomaly reported.There appears to be a hazy look to the inside of the reservoir, resembling condensation, with a slight pattern in certain areas.As the lot number of the affected product was not provided, a list of all 3cx*rx25re products sent to australia in the past 6 months was obtained.Retention samples from this list of product were visually inspected and confirmed to not have this extra coating visual anomaly.Two of the retention samples were then placed into an accelerated aging oven for approximately 24 hours, in order to get warm, and then immediately placed into a refrigerator, in attempts to replicate the condensation; however, no condensation appeared on the units.During blood testing using an expired unit from lot ql17, a similar effect was seen after bovine blood was introduced into the reservoir.The anomaly did not last on the reservoir after the test was completed.Although a definitive root cause could not be determine, this event has been confirmed.All available information has been placed on file in quality management for appropriate tracking, trending and follow up.
|